Latest news
CLL Just Moved a Noncovalent BTK Inhibitor Into First Line
FDA has approved pirtobrutinib for previously untreated CLL or SLL without known 17p deletion. The approval pushes a noncovalent BTK inhibitor into first-line care after a Phase III trial produced a striking progression-free survival advantage over chemoimmunotherapy.
IPM Brief – Issue 7 | The Gate Is the Product
AI genomics market set to hit $9.3B by 2030, but regulation and equity gaps remain unresolved
Japan Approves MRD Testing. Price Will Decide Whether Patients Can Use It.
MS Does Not End at the Clinic Door. It Follows People Into Work, Money and Relationships.
For Drug-Resistant Epilepsy, Surgery Should Not Be the Only Door
Diphtheria Came Back. Remote Communities Are Carrying the Cost.
Gonorrhoea Is Not Disappearing. Too Many Systems Are Failing to See It.
Heart pumps save lives. FDA’s latest Impella alerts show why cardiac device safety cannot stop at approval.
Type 1 diabetes has a kidney problem. FDA is now fast-tracking a possible answer.
Free IPM Alliance Newsletter
Insights on science, policy and access in personalised medicine.